

Table of Contents

Guest Editor for this issue:

R. James White, MD, PhD

Assistant Professor of Medicine,
Pharmacology & Physiology
Division of Pulmonary and
Critical Care Medicine
University of Rochester
Rochester, New York

- 15 Advances in Pulmonary Hypertension CME Section
- 17 Near-Term Novel Therapies for PAH
- 24 Evaluating Recent Therapeutic Trials in Pulmonary Arterial Hypertension: Raising the Bar for Clinical Investigation
- 32 Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH
- 37 CME Self-Assessment Examination
- 42 Pulmonary Hypertension Roundtable: Ethical Considerations for RCTs in PAH
- 47 International Corner

Publisher

Pulmonary Hypertension Association
Carl Hicks, *Board Chair*
Rino Aldrighetti, *President*
Sherrie Borden, *Vice President, Medical and Patient Education*

Publishing Staff

Managing Editor
Deborah L. McBride
McBride Strategic Services
mcbriedeb@aol.com
Design Director
Michael McClain

PHA Office

Pulmonary Hypertension Association
801 Roeder Road., Ste 400
Silver Spring, MD 20910
301-565-3004, 301-565-3994 (fax)
www.PHAssociation.org

© 2009 by Pulmonary Hypertension Association. All rights reserved. None of the contents may be reproduced in any form whatsoever without the written permission of PHA.

Advances in Pulmonary Hypertension is circulated to cardiologists, pulmonologists, rheumatologists and other selected physicians by the Pulmonary Hypertension Association. The contents of the articles are independently determined by the Editor and the Editorial Advisory Board.

Cover Image

A new day is dawning in the treatment of pulmonary arterial hypertension as new therapeutic approaches become available. These advancements are captured visually in Max Hayslette's painting "Tuscan Sunrise." Copyright © Grand Image, Ltd.

Guest Editor's Memo

A New Day for PAH



When the editorial board first considered an issue devoted to recent clinical trial results, clinicians had 6 FDA approved drugs to treat pulmonary arterial hypertension (PAH). We now have 7, and it seems conceivable that we might have an 8th before the end of 2009. With collaborative, international efforts, the pace of progress has quickened in the last 5 years, and indeed, a "New Day is Dawning" on treatment options for our patients.

In this issue, Bob Schilz and I wanted to provide an authoritative update on recent clinical trials and to highlight therapies that have "graduated" from bench science to bedside investigation. An author on the pivotal epoprostenol report, David Langleben has a long perspective and remains committed to bench research on mechanisms of vascular dysfunction in PAH. His article highlights Phases I and II trial data that have been reported only in abstract form at international meetings in the last 2 years. He also invites readers to consider an important question about whether our current therapies address fundamental disease mechanisms. I think readers will especially appreciate the figure illustrating how cicletanine, riociguat, and phospho-diesterase inhibitors are related in the nitric oxide-cyclic GMP signaling pathway.

Murali Chakinala's information-packed article summarizes key data from recently published or presented combination trials including PACES (adding sildenafil), TRIUMPH (adding inhaled treprostinil), and PHIRST (adding tadalafil). A useful table in the paper shows trends in the baseline characteristics of patients over the last decade, and his thoughtful analysis on endpoints highlights the limitations of our current approach in drug development and invites us to "Raise the bar" for future investigations.

(continued on bottom of page 39)

Editor's Memo



Starting with this issue of *Advances in Pulmonary Hypertension*, I am delighted to assume the editor-in-chief position. I am extremely grateful to Ron Oudiz for his productive tenure and his guidance through the process of creating and producing a quality journal. The feedback we have received during Ron's time in charge has been almost uniformly glowing, a testament to his calm leadership. I will do my best to maintain the quality of the journal and provide similar (although possibly less calm) guidance.

The mission of *Advances* has always been to provide, for practicing physicians, cutting edge updates on all aspects of pulmonary hypertension (PH). The journal has, we hope, been accessible and understandable to the diverse readers, including nurses, pharmacists, internists, rheumatologists, pulmonologists, and cardiologists. We have, thus, avoided including primary, original research papers or articles with too narrow a focus.

The overall tenor of *Advances* will continue, unchanged under my editorship. However, I am excited to introduce several new features that we believe will enhance the variety and accessibility of the journal. These 4 new sections will debut in the Summer 2009 issue:

Article Reviews (Section Editors: Drs Todd Bull and Francisco Soto): Brief summaries of recently published papers related to pulmonary vascular disease.

Pulmonary Hypertension Resource Network Corner (Section Editor: Glenna Traiger, RN, MSN): Topics of particular interest to allied health personnel involved in PH, such as nutrition, insurance issues, etc...

Ask the Expert (Section Editor: Dr Myung Park) We will solicit questions related to any

(continued on bottom of page 5)

Editorial Advisory Board

Editor-in-Chief

Richard Channick, MD
Professor of Clinical Medicine
Pulmonary and Critical Care Division
University of California,
San Diego Medical Center
San Diego, California

Immediate Past Editor

Ronald J. Oudiz, MD
Associate Professor of Medicine
The David Geffen School of Medicine
at UCLA
Director, Liu Center for Pulmonary
Hypertension
LA Biomedical Research Institute at
Harbor-UCLA Medical Center
Torrance, California

Editor-in-Chief Elect

Erika Berman Rosenzweig, MD
Associate Professor of Clinical
Pediatrics (in Medicine)
Columbia University,
College of Physicians and Surgeons
Morgan Stanley Children's Hospital
of New York
New York, New York

Associate Editors

Kristin Highland, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care,
Allergy and Sleep Medicine
Medical University of South Carolina
Charleston, South Carolina

Francisco Soto, MD, MS

Director, Pulmonary Hypertension
Program
Pulmonary and Critical Care Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin

Todd Bull, MD

Associate Professor of Medicine
Division of Pulmonary Sciences and
Critical Care Medicine
University of Colorado Health
Sciences Center
Denver, Colorado

Robert Schilz, DO, PhD

Medical Director of Lung
Transplantation and Pulmonary
Vascular Disease
University Hospital of Cleveland
Case Western Reserve University
Cleveland, Ohio

Editorial Board

Charles Burger, MD
Medical Director, PH Clinic
Mayo Clinic
Jacksonville, FL

Karen Fagan, MD

Chief, Division of Pulmonary and
Critical Care Medicine
University of South Alabama
Mobile, Alabama

Eli Gabbay, MD

Lung Transplant Unit
Royal Perth Hospital
Western Australia, Australia

Nick Kim, MD

Assistant Clinical Professor
of Medicine
University of California, San Diego
La Jolla, California

Deborah Jo Levine, MD

University of Texas Health
Science Center at San Antonio
San Antonio, Texas

Omar Minai, MD

Dept of Pulmonary, Allergy and
Critical Care Medicine
Cleveland Clinic
Cleveland, Ohio

Myung Park, MD

Associate Professor of Medicine
Division of Pulmonary Sciences
and Critical Care Medicine
University of Maryland
Baltimore, Maryland

Fernando Torres, MD

Director, Pulmonary Hypertension Clinic
University of Texas Southwestern
Medical Center
Dallas, Texas

Glenna Traiger, RN, MSN

Pulmonary & Critical Care
Pulmonary Hypertension CNS
University of California, Los Angeles
Los Angeles, CA

R. James White, MD, PhD

Assistant Professor of Medicine,
Pharmacology & Physiology
Division of Pulmonary and
Critical Care Medicine
University of Rochester
Rochester, New York

Roham Zamanian, MD

Division of Pulmonary and
Critical Care Medicine
Stanford University Medical Center
Stanford, California

Program Description

The mission of *Advances in Pulmonary Hypertension* is to serve as the premiere forum for state of the art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension. The 2003 Venice revision of the World Health Organization Classification serves as a guide to categories of pulmonary hypertension addressed by the Journal. While focusing on WHO Group I PAH, the other categories (Group II, Left heart disease; Group III, Associated with lung disease and/or hypoxemia; Group IV, Thrombotic and/or Embolic Disease; Group V, Miscellaneous) are also addressed. This mission is achieved by a combination of invited review articles, Roundtable discussions with panels consisting of international experts in PH, and original contributions. In addition, a special section in selected issues entitled "Profiles in Pulmonary Hypertension" recognizes major contributors to the field and serves as an inspiring reminder of the rich and collegial history of dedication to advancing the field.

Objectives

- Provide up-to-date information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension.
- Serve as a forum for presentation and discussion of important issues in the field, including new paradigms of disease understanding and investigational trial design.
- Recognize and preserve the rich history of individuals who have made major contributions to the field via dedication to patient care, innovative research, and furthering the mission of the PH community to cure pulmonary hypertension.

The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD

Chair, SLC
University of Michigan
Health System
Ann Arbor, Michigan

David B. Badesch, MD

SLC Immediate Past-Chair
University of Colorado Health Sciences
Center
Aurora, Colorado

John H. Newman, MD

SLC Vice-Chair
Vanderbilt Medical School
Nashville, Tennessee

Raymond L. Benza, MD

Allegheny General Hospital
Pittsburgh, Pennsylvania

Todd Bull, MD

University of Colorado Health
Sciences Center
Denver, Colorado

Richard Channick, MD

Editor-in-Chief, *Advances in Pulmonary Hypertension*
UCSD Medical Center
La Jolla, California

C. Gregory Elliott, MD

University of Utah School of Medicine
Murray, Utah

Karen A. Fagan, MD

University of South Alabama
Mobile, Alabama

Robert Frantz, MD

Mayo Clinic College of Medicine
Rochester, Minnesota

John Granton, MD

Toronto General Hospital
Toronto, Canada

Nicholas S. Hill, MD

Tufts-New England Medical Center
Boston, Massachusetts

Marius Hoeper, MD

University of Hanover Medical School
Hanover, Germany

Dunbar Ivy, MD

University of Colorado
Denver Health Sciences Center
Denver, Colorado

Zhi-Cheng Jing, MD

Shanghai Pulmonary Hospital
Shanghai, China

Anne M. Keogh, MD

St. Vincent's Public Hospital
Sydney, Australia

Michael J. Krowka, MD

Mayo Clinic
Rochester, Minnesota

James E. Loyd, MD

Vanderbilt University Medical Center
Nashville, Tennessee

Michael Mathier, MD

University of Pittsburgh
Medical Center
Pittsburgh, Pennsylvania

Michael D. McGoon, MD

Immediate Past-Chair,
PHA Board of Trustees
Mayo Clinic
Rochester, Minnesota

Ronald J. Oudiz, MD

Immediate Past Editor-in-Chief,
Advances in Pulmonary Hypertension
Liu Center for Pulmonary
Hypertension at Harbor – UCLA
Medical Center
Torrance, California

Andrew Peacock, MD

Western Infirmary
Glasgow, Scotland, United Kingdom

Erika Berman Rosenzweig, MD

Editor-In-Chief Elect, *Advances in Pulmonary Hypertension*
Columbia Presbyterian Medical Center
New York, New York

Ivan Robbins, MD

Chair, Scientific Sessions Committee
Vanderbilt University
Nashville, Tennessee

Julio Sandoval, MD

National Institute of Cardiology
of Mexico
Tlalpan, Mexico

Richard Silver, MD

Medical University of South Carolina
Charleston, South Carolina

Victor F. Tapson, MD

Duke University Medical Center
Durham, North Carolina

Jason Yuan, MD, PhD

Chair, PHA Research Committee
University of California, San Diego
La Jolla, California

Liaisons

Arlene Schiro, NP (voting)
Chair, PH Resource Network
Massachusetts General Hospital
Boston, MA

Harry Rozakis

Board Liaison

Emeritus Members

Bruce H. Brundage, MD
St. Charles Medical Center - Bend
Bend, Oregon

Alfred P. Fishman, MD

University of Pennsylvania
Health System
Philadelphia, Pennsylvania

The Mission of the Scientific Leadership Council is to provide medical and scientific guidance and support to the PHA by:

- Developing and disseminating knowledge for diagnosing and treating pulmonary hypertension
- Advocating for patients with pulmonary hypertension
- Increasing involvement of basic and clinical researchers and practitioners

More information on PHA's Scientific Leadership Council and associated committees can be found at:
www.PHAssociation.org/SLC/